Heidelberg Pharma AG announces updated guidance

EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Change in Forecast
Heidelberg Pharma AG announces updated guidance

18-Jun-2024 / 13:47 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc announcement

Disclosure of inside information under Article 17 of Regulation (EU) No
596/2014

Heidelberg Pharma AG Announces Updated Guidance

Ladenburg, Germany, 18 June 2024 - Heidelberg Pharma AG (FSE: HPHA), a
clinical stage biotech company developing innovative Antibody Drug
Conjugates (ADCs), today announces that it has adjusted its guidance for the
current fiscal year published on 25 March 2024.

The Heidelberg Pharma Group expects for the financial year 2024 sales and
other income between EUR 9.0 million and EUR 12.0 million (previously: EUR
11.0 million to EUR 15.0 million). The reason for the lower sales is that
expected sales are likely to be delayed due to developments at the license
partners. Operating expenses will remain between EUR 36.0 million and EUR
40.0 million. Based on these adjustments, an operating result (EBIT) between
EUR -25.5 million and EUR -29.5 million is expected (previously: EUR -23.5
million to EUR -27.5 million).

For 2024, Heidelberg Pharma anticipates cash requirements of EUR 18.0
million to EUR 22.0 million (previously: EUR 28.0 million to EUR 32.0
million). Monthly cash consumption is expected to range between EUR 1.5
million and EUR 1.8 million per month (previously: EUR 2.3 million and EUR
2.7 million). Based on the existing planning and available funds, the
company's financing is secured until mid-2025.

Taking into account a further expected payment of USD 75.0 million from
HealthCare Royalty, the company assumes that financing will be available
until the end of 2026.


End of Inside Information

---------------------------------------------------------------------------

Information and Explanation of the Issuer to this announcement:

About Heidelberg Pharma

Heidelberg Pharma develops novel drugs based on its ADC technologies for the
targeted and highly effective treatment of cancer. ADCs are antibody-drug
conjugates that combine the specificity of antibodies with the efficacy of
toxins to fight cancer. Selected antibodies are loaded with cytotoxic
compounds, the so-called payloads, that are transported into diseased cells.
Inside the cells, the toxins then unleash their effect and kill the diseased
cells.

Heidelberg Pharma is the first company to use the mushroom toxin Amanitin in
cancer therapy by exploiting the toxin's biological mechanism of action with
its innovative ATAC technology as a new therapeutic modality. It offers the
opportunity to overcome resistance of cancer cells against therapeutic
agents currently used and to eliminate dormant tumor cells, which typically
survive current therapies and are responsible for tumor relapse and
metastasis. This could lead to significant advances in cancer therapy - even
for patients who no longer respond to any other treatment. The most advanced
product candidate HDP-101 is a BCMA-ATAC for the indication multiple
myeloma, which is currently in clinical development.

In addition to Amanitin, alternative payloads also expand the ADC platform
technologies of Heidelberg Pharma to develop targeted and highly effective
ADCs for the treatment of a variety of malignant hematologic and solid
tumors.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg,
Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 /
WKN A11QVV / Symbol HPHA. More information is available at
www.heidelberg-pharma.com.

ATAC® is a registered trademark of Heidelberg Pharma Research GmbH.

    Contact Heidelberg Pharma AG Sylvia       IR/PR-Support MC Services AG
              Wimmer Director Corporate       Katja Arnold (CIRO) Managing
      Communications Tel.: +49 89 41 31    Director & Partner Tel.: +49 89
                          38-29 E-mail:                 210 228-40 E-mail:
              (1)investors@hdpharma.com     (1)katja.arnold@mc-services.eu
           Gregor-Mendel-Str. 22, 68526                                 1.
                          Ladenburg  1.    mailto:katja.arnold@mc-services
          mailto:investors@hdpharma.com                                .eu
   International IR/PR-Support Optimum
   Strategic Communications Mary Clark,
   Zoe Bolt, Katie Flint Tel: +44 20
   3882 9621 E-mail:
   (1)HeidelbergPharma@optimumcomms.com
   1.
   mailto:HeidelbergPharma@optimumcomms
   .com%0d

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "will" "should" "future", "potential" or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to place
undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.


---------------------------------------------------------------------------

18-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Heidelberg Pharma AG
                   Gregor-Mendel-Str. 22
                   68526 Ladenburg
                   Germany
   Phone:          +49 (0)89 41 31 38 - 0
   Fax:            +49 (0)89 41 31 38 - 99
   E-mail:         investors@hdpharma.com
   Internet:       www.heidelberg-pharma.com
   ISIN:           DE000A11QVV0
   WKN:            A11QVV
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1927813

End of Announcement EQS News Service
---------------------------------------------------------------------------

1927813 18-Jun-2024 CET/CEST